Xcout Intel
PAhR Therapeutics
Pahr Therapeutics, Inc. is a biotechnology company focused on developing new treatments for pulmonary arterial hypertension (PAH). The company recently raised $14 million in seed funding to support its therapeutic development efforts.
Subscribe to see PAhR Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
PAhR Therapeutics at a glance
PAhR Therapeutics is a biotechnology company headquartered in United States. Its most recent funding round, Seed, raised $14M in July 2025. Xcout tracks 9 named people at PAhR Therapeutics, including Neil Buckley (President).
PAhR Therapeutics leadership
- Neil BuckleyPresident
- Makoto Okazawaco-founder
- Ryotaro Asanoco-founder
- Yoshikazu Nakaokaco-founder
- AMANDA CREEDONExecutive Officer
- Neil BuckleyExecutive Officer
3 more named people on record for PAhR Therapeutics, with roles, board committees and tenure — see the full roster →
PAhR Therapeutics funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $14M | 4 named | |
| SEC Form D filing | $4.7M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
PAhR Therapeutics competitors
A few of PAhR Therapeutics's closest competitors — see the full list of competitors and alternatives →
Cirrus Therapeutics, Inc. is an early-stage biotechnology company that has raised seed funding for its therapeutic research operations.
Bellerophon Therapeutics, Inc. is a clinical-stage biopharmaceutical company that engages in the development of products to address pulmonary hypertension related to interstitial lung disease.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Eleven P15 Inc. is a biotechnology company focused on developing early-detection biomarkers and genetically-targeted therapeutics for idiopathic pulmonary fibrosis (IPF). The company aims to improve diagnosis and treatment outcomes for patients suffering from this fatal lung disease.
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biotechnology company headquartered in Malvern, Pennsylvania, with additional operations in San Diego, California. The company focuses on the discovery and development of novel biopharmaceuticals for cardiovascular and other severe diseases.
Sunterra Bio is a biopharmaceutical company focused on developing inhaled small-molecule therapies for rare pulmonary diseases. Headquartered in Carlsbad, California, the company advances targeted treatments for respiratory conditions.
Get PAhR Therapeutics's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on PAhR Therapeutics in Xcout Intel
- 9 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access